Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer at 89BIO, INC.
Net worth: 2 M $ as of 30/04/2024
Quoc Le-Nguyen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| 89BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2019 | - |
Career history of Quoc Le-Nguyen
Former positions of Quoc Le-Nguyen
| Companies | Position | Start | End |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2015 | 01/07/2018 |
| BAYER AG | Corporate Officer/Principal | 01/09/2007 | 01/09/2013 |
Training of Quoc Le-Nguyen
| University of California | Undergraduate Degree |
Statistics
International
| United States | 4 |
| Germany | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| 89BIO, INC. | Health Technology |
| BAYER AG | Health Technology |
| Private companies | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Quoc Le-Nguyen
- Experience